Extensions for Using Data Elements from FHIR R4 in FHIR R4B - Downloaded Version null See the Directory of published versions
| Official URL: http://hl7.org/fhir/uv/xver/ValueSet/R4-v2-0292-for-R4B | Version: 0.1.0 | |||
| Standards status: Trial-use | Maturity Level: 0 | Computable Name: R4V20292ForR4B | ||
This cross-version ValueSet represents content from http://terminology.hl7.org/ValueSet/v2-0292|2.9 for use in FHIR R4B.
This value set is part of the cross-version definitions generated to enable use of the
value set http://terminology.hl7.org/ValueSet/v2-0292|2.9 as defined in FHIR R4
in FHIR R4B.
The source value set is bound to the following FHIR R4 elements:
Note that all concepts are included in this cross-version definition because no concepts have compatible representations
Following are the generation technical comments:
FHIR ValueSet http://terminology.hl7.org/ValueSet/v2-0292|2.9, defined in FHIR R4 does not have any mapping to FHIR R4B
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://terminology.hl7.org/CodeSystem/v2-0292 version 📍2.9| Code | Display |
| 01 | DTP |
| 02 | OPV |
| 03 | MMR |
| 04 | M/R |
| 05 | measles |
| 06 | rubella |
| 07 | mumps |
| 08 | Hep B, adolescent or pediatric |
| 09 | Td (adult) |
| 10 | IPV |
| 100 | pneumococcal conjugate |
| 101 | typhoid, ViCPs |
| 102 | DTP-Hib-Hep B |
| 103 | meningococcal C conjugate |
| 104 | Hep A-Hep B |
| 105 | vaccinia (smallpox) diluted |
| 106 | DTaP, 5 pertussis antigens6 |
| 107 | DTaP, NOS |
| 108 | meningococcal, NOS |
| 109 | pneumococcal, NOS |
| 11 | pertussis |
| 110 | DTaP-Hep B-IPV |
| 111 | influenza, live, intranasal |
| 112 | tetanus toxoid, NOS |
| 113 | Td (adult) |
| 114 | meningococcal A,C,Y,W-135 diphtheria conjugate |
| 115 | Tdap |
| 116 | rotavirus, pentavalent |
| 117 | VZIG (IND) |
| 118 | HPV, bivalent |
| 119 | rotavirus, monovalent |
| 12 | diphtheria antitoxin |
| 120 | DTaP-Hib-IPV |
| 121 | zoster |
| 122 | rotavirus, NOS1 |
| 13 | TIG |
| 14 | IG, NOS |
| 15 | influenza, split (incl. purified surface antigen) |
| 16 | influenza, whole |
| 17 | Hib, NOS |
| 18 | rabies, intramuscular injection |
| 19 | BCG |
| 20 | DTaP |
| 21 | varicella |
| 22 | DTP-Hib |
| 23 | plague |
| 24 | anthrax |
| 25 | typhoid, oral |
| 26 | cholera |
| 27 | botulinum antitoxin |
| 28 | DT (pediatric) |
| 29 | CMVIG |
| 30 | HBIG |
| 31 | Hep A, pediatric, NOS |
| 32 | meningococcal |
| 33 | pneumococcal |
| 34 | RIG |
| 35 | tetanus toxoid |
| 36 | VZIG |
| 37 | yellow fever |
| 38 | rubella/mumps |
| 39 | Japanese encephalitis |
| 40 | rabies, intradermal injection |
| 41 | typhoid, parenteral |
| 42 | Hep B, adolescent/high risk infant2 |
| 43 | Hep B, adult4 |
| 44 | Hep B, dialysis |
| 45 | Hep B, NOS |
| 46 | Hib (PRP-D) |
| 47 | Hib (HbOC) |
| 48 | Hib (PRP-T) |
| 49 | Hib (PRP-OMP) |
| 50 | DTaP-Hib |
| 51 | Hib-Hep B |
| 52 | Hep A, adult |
| 53 | typhoid, parenteral, AKD (U.S. military) |
| 54 | adenovirus, type 4 |
| 55 | adenovirus, type 7 |
| 56 | dengue fever |
| 57 | hantavirus |
| 58 | Hep C |
| 59 | Hep E |
| 60 | herpes simplex 2 |
| 61 | HIV |
| 62 | HPV, quadrivalent |
| 63 | Junin virus |
| 64 | leishmaniasis |
| 65 | leprosy |
| 66 | Lyme disease |
| 67 | malaria |
| 68 | melanoma |
| 69 | parainfluenza-3 |
| 70 | Q fever |
| 71 | RSV-IGIV |
| 72 | rheumatic fever |
| 73 | Rift Valley fever |
| 74 | rotavirus, tetravalent |
| 75 | vaccinia (smallpox) |
| 76 | Staphylococcus bacterio lysate |
| 77 | tick-borne encephalitis |
| 78 | tularemia vaccine |
| 79 | vaccinia immune globulin |
| 80 | VEE, live |
| 81 | VEE, inactivated |
| 82 | adenovirus, NOS1 |
| 83 | Hep A, ped/adol, 2 dose |
| 84 | Hep A, ped/adol, 3 dose |
| 85 | Hep A, NOS |
| 86 | IG |
| 87 | IGIV |
| 88 | influenza, NOS |
| 89 | polio, NOS |
| 90 | rabies, NOS |
| 91 | typhoid, NOS |
| 92 | VEE, NOS |
| 93 | RSV-MAb |
| 94 | MMRV |
| 95 | TST-OT tine test |
| 96 | TST-PPD intradermal |
| 97 | TST-PPD tine test |
| 98 | TST, NOS |
| 99 | RESERVED - do not use3 |
| 998 | no vaccine administered5 |
| 999 | unknown |
This value set expansion contains 124 concepts.
| System | Version | Code | Display | JSON | XML |
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 01 | DTP | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 02 | OPV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 03 | MMR | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 04 | M/R | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 05 | measles | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 06 | rubella | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 07 | mumps | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 08 | Hep B, adolescent or pediatric | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 09 | Td (adult) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 10 | IPV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 100 | pneumococcal conjugate | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 101 | typhoid, ViCPs | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 102 | DTP-Hib-Hep B | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 103 | meningococcal C conjugate | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 104 | Hep A-Hep B | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 105 | vaccinia (smallpox) diluted | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 106 | DTaP, 5 pertussis antigens6 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 107 | DTaP, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 108 | meningococcal, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 109 | pneumococcal, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 11 | pertussis | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 110 | DTaP-Hep B-IPV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 111 | influenza, live, intranasal | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 112 | tetanus toxoid, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 113 | Td (adult) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 114 | meningococcal A,C,Y,W-135 diphtheria conjugate | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 115 | Tdap | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 116 | rotavirus, pentavalent | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 117 | VZIG (IND) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 118 | HPV, bivalent | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 119 | rotavirus, monovalent | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 12 | diphtheria antitoxin | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 120 | DTaP-Hib-IPV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 121 | zoster | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 122 | rotavirus, NOS1 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 13 | TIG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 14 | IG, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 15 | influenza, split (incl. purified surface antigen) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 16 | influenza, whole | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 17 | Hib, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 18 | rabies, intramuscular injection | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 19 | BCG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 20 | DTaP | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 21 | varicella | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 22 | DTP-Hib | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 23 | plague | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 24 | anthrax | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 25 | typhoid, oral | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 26 | cholera | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 27 | botulinum antitoxin | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 28 | DT (pediatric) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 29 | CMVIG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 30 | HBIG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 31 | Hep A, pediatric, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 32 | meningococcal | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 33 | pneumococcal | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 34 | RIG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 35 | tetanus toxoid | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 36 | VZIG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 37 | yellow fever | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 38 | rubella/mumps | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 39 | Japanese encephalitis | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 40 | rabies, intradermal injection | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 41 | typhoid, parenteral | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 42 | Hep B, adolescent/high risk infant2 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 43 | Hep B, adult4 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 44 | Hep B, dialysis | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 45 | Hep B, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 46 | Hib (PRP-D) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 47 | Hib (HbOC) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 48 | Hib (PRP-T) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 49 | Hib (PRP-OMP) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 50 | DTaP-Hib | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 51 | Hib-Hep B | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 52 | Hep A, adult | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 53 | typhoid, parenteral, AKD (U.S. military) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 54 | adenovirus, type 4 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 55 | adenovirus, type 7 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 56 | dengue fever | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 57 | hantavirus | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 58 | Hep C | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 59 | Hep E | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 60 | herpes simplex 2 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 61 | HIV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 62 | HPV, quadrivalent | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 63 | Junin virus | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 64 | leishmaniasis | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 65 | leprosy | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 66 | Lyme disease | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 67 | malaria | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 68 | melanoma | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 69 | parainfluenza-3 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 70 | Q fever | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 71 | RSV-IGIV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 72 | rheumatic fever | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 73 | Rift Valley fever | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 74 | rotavirus, tetravalent | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 75 | vaccinia (smallpox) | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 76 | Staphylococcus bacterio lysate | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 77 | tick-borne encephalitis | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 78 | tularemia vaccine | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 79 | vaccinia immune globulin | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 80 | VEE, live | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 81 | VEE, inactivated | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 82 | adenovirus, NOS1 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 83 | Hep A, ped/adol, 2 dose | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 84 | Hep A, ped/adol, 3 dose | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 85 | Hep A, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 86 | IG | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 87 | IGIV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 88 | influenza, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 89 | polio, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 90 | rabies, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 91 | typhoid, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 92 | VEE, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 93 | RSV-MAb | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 94 | MMRV | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 95 | TST-OT tine test | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 96 | TST-PPD intradermal | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 97 | TST-PPD tine test | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 98 | TST, NOS | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 99 | RESERVED - do not use3 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 998 | no vaccine administered5 | ||
http://terminology.hl7.org/CodeSystem/v2-0292 | 2.9 | 999 | unknown |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |